Enoxaparin has become the treatment of choice for various thromboembolic diseases. In most patients with end-stage renal disease (ESRD), prophylactic dosage of enoxaparin does not appear to be associated with an increased bleeding risk and can be used without the need for monitoring and adjustment of regimens. Empirical dose adjustment and biological monitoring seem to be necessary along with therapeutic doses. Anti-factor Xa poorly predicts the degree of anticoagulation in ESRD patients given enoxaparin.
http://www.nature.com/ki/journal/v84/n3/full/ki2013163a.html
Silvia Lai and Bettina Coppola
Kidney Int 84: 433-436; doi:10.1038/ki.2013.163
Additional Info
-
Language:
English -
Contains Audio:
No -
Content Type:
Articles -
Source:
KI -
Year:
2013 -
Members Only:
No